이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행성 요로상피암 및 선택 섬유모세포 성장 인자 수용체(FGFR) 유전자 이상을 가진 참가자를 대상으로 빈플루닌, 도세탁셀 또는 펨브롤리주맙과 비교한 에르다피티닙 연구 (THOR)

2026년 11월 2일 업데이트: Janssen Research & Development, LLC

진행성 요로상피암 및 특정 FGFR 유전자 이상 환자를 대상으로 Erdafitinib을 Vinflunine, Docetaxel 또는 Pembrolizumab과 비교한 3상 연구

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-[L]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).

연구 개요

상세 설명

A study of erdafitinib versus standard of care, consisting of chemotherapy (docetaxel or vinflunine) or anti-PD-(L) 1 agent pembrolizumab, in participants with advanced urothelial cancer and selected FGFR aberrations who have progressed on or after 1 or 2 prior treatments, at least 1 of which includes an anti-PD-(L) 1 agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2). It will consist of screening, treatment phase (from randomization until disease progression, intolerable toxicity, withdrawal of consent or decision by investigator to discontinue treatment, post-treatment follow-up (from end-of-treatment to participants death, withdraws consent, lost to follow-up study completion for the respective cohort, whichever comes first). The study will have long term extension (LTE) period after clinical cutoff date is achieved for final analysis of each cohort and participants eligible in the opinion of the investigator, will continue to benefit from the study intervention. Efficacy, pharmacokinetics, biomarkers, patient reported outcomes, medical resource utilization and safety will be assessed.

연구 유형

중재적

등록 (실제)

629

단계

  • 3단계

확장된 액세스

승인됨 대중에게 판매합니다. 확장 액세스 기록을 참조하세요.

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Athens, 그리스, 15125
        • Athens Medical Center
      • Athens, 그리스, 11526
        • Errikos Dunant Hospital Center
      • Athens, 그리스, 15562
        • Metropolitan General A E
      • Athens, 그리스, 115 28
        • University of Athens Medical School - Regional General Hospi
      • Larissa, 그리스, 41110
        • University Hospital Of Larissa
      • Pátrai, 그리스, 26504
        • University General Hospital of Rio Patras
      • Thessaloniki, 그리스, 54645
        • Euromedica General Clinic
      • Thessaloniki, 그리스, 14564
        • Interbalkan European Medical Center
      • Thessaloniki, 그리스, 56403
        • Papageorgiou General Hospital Of Thessaloniki
      • Amsterdam, 네덜란드, 1066 CX
        • Antoni van Leeuwenhoek
      • Nieuwegein, 네덜란드, 3430 EM
        • St. Antonius Ziekenhuis Nieuwegein
      • The Hague, 네덜란드, 2545 CH
        • Haga ziekenhuis
      • Kaohsiung City, 대만, 807
        • Kaohsiung Medical University Chung Ho Memorial Hospital
      • Niao-Sung Hsiang, 대만, 833
        • Chang Gung Medical Foundation
      • Taichung, 대만, 40447
        • China Medical University Hospital
      • Taichung, 대만, 40705
        • Taichung Veterans General Hospital
      • Tainan, 대만, 70403
        • National Cheng Kung University Hospital
      • Tainan, 대만, 710
        • Chi Mei Medical Center Yong Kang
      • Taipei, 대만, 10002
        • National Taiwan University Hospital
      • Taipei, 대만, 11217
        • Taipei Veterans General Hospital
      • Taipei, 대만, 10449
        • Mackay Memorial Hospital
      • Taipei, 대만, 11259
        • Koo Foundation Sun Yat-Sen Cancer Center
      • Taoyuan, 대만, 333
        • Chang-Gung Memorial Hospital, LinKou Branch
      • Busan, 대한민국, 49241
        • Pusan National University Hospital
      • Daejeon, 대한민국, 35015
        • Chungnam National University Hospital
      • Goyang-si, 대한민국, 410-769
        • National Cancer Center
      • Gwangju, 대한민국, 61469
        • Chonnam National University Hospital
      • Gyeonggi-do, 대한민국, 13620
        • Seoul National University Bundang Hospital
      • Incheon, 대한민국, 21565
        • Gachon University Gil Medical Center
      • Seoul, 대한민국, 03080
        • Seoul National University Hospital
      • Seoul, 대한민국, 03722
        • Severance Hospital Yonsei University Health System
      • Seoul, 대한민국, 03181
        • Kangbuk Samsung Hospital
      • Seoul, 대한민국, 02841
        • Korea University Anam Hospital
      • Seoul, 대한민국, 135-710
        • Samsung Medical Center
      • Wŏnju, 대한민국, 26426
        • Yonsei University Wonju Severance Christian Hospital
      • Berlin, 독일, 10967
        • Vivantes Klinikum Am Urban
      • Braunschweig, 독일, 38126
        • Stadtisches Klinikum Braunschweig gGmbH-Klinik fur Urologie und Uroonkologie
      • Dresden, 독일, 01307
        • Universitatsklinikum Carl Gustav Carcus Dresden
      • Düsseldorf, 독일, 40225
        • Universitaetsklinikum Duesseldorf
      • Erlangen, 독일, 91054
        • Friedrich-Alexander Universitaet Urologische Universitaetskl
      • Frankfurt, 독일, 60590
        • Universitatsklinikum Frankfurt
      • Freiburg im Breisgau, 독일, 79106
        • Universitatsklinikum Freiburg
      • Greifswald, 독일, 17475
        • Universitätsmedizin Greifswald
      • Göttingen, 독일, 37099
        • Universitatsmedizin Gottingen
      • Hamburg, 독일, 22763
        • Asklepios Klinik Altona
      • Hanover, 독일, 30625
        • Medizinische Hochschule Hannover
      • Lübeck, 독일, 23538
        • Universitatsklinikum Schleswig Holstein Campus Lubeck
      • Mannheim, 독일, 68167
        • Medizinische Fakultät Mannheim der Universität Heidelberg
      • Münster, 독일, 48149
        • Universitaetsklinikum Muenster
      • Nürtingen, 독일, 72622
        • Studienpraxis Urologie Drs. Feyerabend
      • Regensburg, 독일, 93053
        • Caritas-Krankenhaus St. Josef
      • Rostock, 독일, 18057
        • Universitaetsmedizin Rostock
      • Velbert, 독일, 42551
        • MVZ-Onkologie Velbert GbR
      • Weiden, 독일, 92637
        • Kliniken Nordoberpfalz AG/Klinikum Weiden
      • Barnaul, 러시아 제국, 656049
        • Altai Regional Oncology Dispensary
      • Chelyabinsk, 러시아 제국, 454087
        • Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine
      • Irkutsk, 러시아 제국, 664035
        • Irkutsk Regional Oncology Dispensary
      • Ivanovo, 러시아 제국, 153040
        • Ivanovo Regional Oncology Dispensary
      • Kostroma, 러시아 제국, 156005
        • Kostroma regional oncology dispensary
      • Kuzmolovsky, 러시아 제국, 188663
        • Leningrad Regional Oncology Dispensary
      • Moscow, 러시아 제국, 105077
        • City Clinical Hospital n.a. D.D.Pletnev
      • Moscow, 러시아 제국, 117997
        • Russian Scientific Center of Roentgenoradiology
      • Moscow, 러시아 제국, 119991
        • I.M. Sechenov First Moscow State Medical University
      • Moscow, 러시아 제국, 125284
        • Hertzen Oncology Research Institute
      • Moscow, 러시아 제국, 115478
        • FSBSI 'N. N. Blokhin Russian Cancer Research Center'
      • Nal'chik, 러시아 제국, 360017
        • City Clinical Hospital #1
      • Nizhny Novgorod, 러시아 제국, 603109
        • Privolzhsky District Medical Center under the Federal Medico-Biological Agency
      • Omsk, 러시아 제국, 644013
        • Clinical Oncology Dispensary
      • Pyatigorsk, 러시아 제국, 357502
        • GBUZ of Stavropol region Pyatigorsk Oncological Dispensary
      • Saint Petersburg, 러시아 제국, 196603
        • Private Medical Institution Euromedservice
      • Saint Petersburg, 러시아 제국, 197758
        • Russian Scientific Center of Radiology and Surgical Technologies
      • Saint Petersburg, 러시아 제국, 192148
        • LLC 'Strategic Medical Systems'
      • Saint Petersburg, 러시아 제국, 195067
        • Clinical hopital n/a Petra velikogo
      • Saint Petersburg, 러시아 제국, 197022
        • Pavlov First Saint Petersburg State Medical University
      • Saint Petersburg, 러시아 제국, 197758
        • Saint-Petersburg Clinical Scientific And Practical Center For Special Types Of Medical Care
      • Saransk, 러시아 제국, 430032
        • FGBOU Vo Mordovian National Research State University N. A. N.P. Ogareva
      • Saratov, 러시아 제국, 410000
        • Saratov State Medical University
      • Smolensk, 러시아 제국, 214031
        • LLC Uromed
      • Sochi, 러시아 제국, 354057
        • GBUZ Oncology Centre #2 of Healthcare Department of Krasno
      • Tyumen, 러시아 제국, 625041
        • Multifunctional clinical medical center 'Medical city'
      • Ufa, 러시아 제국, 450000
        • Bashkiria State Medical University
      • Vologda, 러시아 제국, 160012
        • Vologda Regional Oncological Dispensary
      • Aguascalientes, 멕시코, 20230
        • Medicos Especialistas en Cancer, S.C.
      • Chihuahua City, 멕시코, 31000
        • Centro Estatal de Cancerología de Chihuahua
      • Naucalpan, 멕시코, 53100
        • Oncologia Integral Satelite
    • Alaska
      • Anchorage, Alaska, 미국, 99503
        • Alaska Urological Institute dba Alaska Clinical Research Center
    • California
      • Sacramento, California, 미국, 95817
        • University of Calif Davis Medical Center
      • St. Helena, California, 미국, 94574
        • St. Helena Hospital - Martin-O'Neil Cancer Center
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20007
        • MedStar Georgetown University Hospital
    • Florida
      • Miami, Florida, 미국, 33136
        • University of Miami Sylvester Cancer Center
      • Orange, Florida, 미국, 32763
        • Mid Florida Hematology Oncology
    • Georgia
      • Atlanta, Georgia, 미국, 30318-0922
        • Piedmont Cancer Institute
    • Illinois
      • Chicago, Illinois, 미국, 60612
        • Rush University
      • Hines, Illinois, 미국, 60141
        • Edward Hines Jr V A Hospital
    • Kentucky
      • Louisville, Kentucky, 미국, 40207
        • Norton Cancer Institute
    • Maryland
      • Lanham, Maryland, 미국, 20706
        • Maryland Oncology Hematology, PA
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109-5000
        • University of Michigan Health System
    • Nevada
      • Reno, Nevada, 미국, 89509
        • VA Sierra Nevada Health Care System
    • New Hampshire
      • Lebanon, New Hampshire, 미국, 03756
        • Dartmouth Hitchcock Medical Center
    • New York
      • New York, New York, 미국, 10029
        • Weill Cornell Medical College
      • The Bronx, New York, 미국, 10461
        • Montefiore Medical Center
    • North Carolina
      • Charlotte, North Carolina, 미국, 28204
        • Levine Cancer Institute, Carolinas HealthCare System
      • Salisbury, North Carolina, 미국, 28144
        • W G Bill Hefner VA Medical Center
    • Ohio
      • Cincinnati, Ohio, 미국, 45242
        • Oncology Hematology Care
    • Texas
      • Fort Worth, Texas, 미국, 76104
        • The Center for Cancer and Blood Disorders
      • Houston, Texas, 미국, 77030
        • MD Anderson Cancer Center
      • Houston, Texas, 미국, 77024
        • Texas Oncology-Memorial City
      • Tyler, Texas, 미국, 75702
        • Texas Oncology Tyler
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • INOVA Dwiight &Martha Schar Cancer Institute
      • Norfolk, Virginia, 미국, 23502
        • Virginia Oncology Associates
    • Washington
      • Seattle, Washington, 미국, 98108
        • VA Puget Sound Healthcare System
      • Aalst, 벨기에, 9300
        • OLV Ziekenhuis Aalst
      • Antwerp, 벨기에, 2020
        • ZNA Middelheim
      • Brussels, 벨기에, 1200
        • Cliniques Universitaires Saint Luc
      • Charleroi, 벨기에, 6000
        • Clinique Notre Dame de Grâce
      • Ghent, 벨기에, 9000
        • AZ Maria Middelares
      • Ghent, 벨기에, 9000
        • UZ Gent
      • Liège, 벨기에, 4000
        • CHC MontLegia
      • Wilrijk, 벨기에, 2610
        • Sint-Augustinus AZ
      • Yvoir, 벨기에, 5530
        • CHU UCL Namur - Site Godinne
      • Pleven, 불가리아, 5800
        • UMHAT 'Dr. Georgi Stranski', EAD
      • Plovdiv, 불가리아, 4004
        • Complex Oncology Center - Plovdiv EOOD
      • Sofia, 불가리아, 1407
        • Multiprofile Hospital for Active Treatment 'Tokuda Hospital Sofia'
      • Sofia, 불가리아, 1797
        • UMHAT Sofia Med
      • Varna, 불가리아, 9010
        • Multiprofile Hospital for Active Treatment 'Sveta Marina' EAD
      • Barretos, 브라질, 14784-400
        • Fundacao Pio XII
      • Belo Horizonte, 브라질, 30130-100
        • Universidade Federal De Minas Gerais - Hospital das Clínicas
      • Belo Horizonte, 브라질, 30380-472
        • Nucleo de Ensino e Pesquisa do Instituto Mario Penna
      • Curitiba, 브라질, 80530-010
        • Instituto de Oncologia do Parana
      • Curitiba, 브라질, 81520 060
        • Liga Paranaense de Combate ao Cancer
      • Goiânia, 브라질, 74605-070
        • Associacao de Combate ao Cancer em Goias - Hospital de Cancer Araujo Jorge
      • Itajaí, 브라질, 88301-220
        • Clínica de Neoplasias Litoral Ltda.
      • Jaú, 브라질, 17210 080
        • Fundacao Doutor Amaral Carvalho
      • Natal, 브라질, 59075-740
        • Liga Norte Riograndense Contra O Cancer
      • Porto Alegre, 브라질, 90035-903
        • Hospital das Clinicas de Porto Alegre
      • Porto Alegre, 브라질, 91350 200
        • Hospital Nossa Senhora da Conceicao S A
      • Rio de Janeiro, 브라질, 22250 905
        • Oncoclinicas Rio de Janeiro S A
      • Rio de Janeiro, 브라질, 20231 050
        • Ministerio da Saude Instituto Nacional do Cancer
      • Salvador, 브라질, 41253-190
        • Hospital Sao Rafael
      • Santo André, 브라질, 09060-650
        • CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
      • Sorocaba, 브라질, 18030-005
        • Instituto de Oncologia de Sorocaba Onco Clinicas Especializadas
      • São José do Rio Preto, 브라질, 15090-000
        • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
      • São Paulo, 브라질, 04502-001
        • Instituto D Or de Pesquisa e Ensino IDOR
      • São Paulo, 브라질, 01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo, 브라질, 05652 900
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, 브라질, 03102-002
        • Instituto Brasileiro de Controle do Cancer - Sao Camilo Oncologia
      • São Paulo, 브라질, 01308 050
        • Sociedade Beneficente de Senhoras Hospital Sirio Libanes 1
      • Badajoz, 스페인, 06006
        • Hosp. Univ. Infanta Cristina
      • Badalona, 스페인, 08916
        • Institut Català D'Oncologia-Hospital Universitari Germans Trias I Pujol
      • Barcelona, 스페인, 08041
        • Hosp. de La Santa Creu I Sant Pau
      • Barcelona, 스페인, 08036
        • Hosp Clinic de Barcelona
      • Cáceres, 스페인, 10003
        • Hosp. San Pedro de Alcantara
      • Córdoba, 스페인, 14004
        • Hosp Reina Sofia
      • Granada, 스페인, 18014
        • Hosp. Univ. Virgen de Las Nieves
      • Jaén, 스페인, 23007
        • Complejo Hospitalario de Jaen
      • Las Palmas de Gran Canaria, 스페인, 35016
        • Hosp. Univ. Insular de Gran Canaria
      • Lugo, 스페인, 27003
        • Hosp. Univ. Lucus Augusti
      • Madrid, 스페인, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, 스페인, 28046
        • Hosp. Univ. La Paz
      • Majadahonda, 스페인, 28220
        • Hosp. Univ. Pta. de Hierro Majadahonda
      • Manresa, 스페인, 08243
        • ALTHAIA, Xarxa Assistencial Universitària de Manresa
      • Pamplona, 스페인, 31008
        • Hosp. de Navarra
      • Seville, 스페인, 41013
        • Hosp. Virgen Del Rocio
      • Seville, 스페인, 41009
        • Hosp. Virgen Macarena
      • Valencia, 스페인, 46014
        • Hosp. Gral. Univ. Valencia
      • Valencia, 스페인, 46026
        • Hosp. Univ. I Politecni La Fe
      • Zaragoza, 스페인, 50009
        • Hosp. Univ. Miguel Servet
      • Buenos Aires, 아르헨티나, C1426AGE
        • Centro Oncológico Korben
      • Buenos Aires, 아르헨티나, C1419AHN
        • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
      • Buenos Aires, 아르헨티나, C1431FWN
        • CEMIC Saavedra
      • Córdoba, 아르헨티나, X5000KPH
        • Centro Urologico Profesor Bengio
      • Córdoba, 아르헨티나, C5000
        • Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
      • Mar del Plata, 아르헨티나, B7602CBM
        • Hospital Privado de Comunidad
      • Pergamino, 아르헨티나, B2700CPM
        • Centro de Investigacion Pergamino SA
      • Viedma, 아르헨티나, R8500ACE
        • Clínica Viedma
      • Bristol, 영국, BS2 8ED
        • University Hospitals Bristol - Bristol Haematology & Oncolog
      • London, 영국, W1G 6AD
        • Sarah Cannon Research Institute
      • London, 영국, W6 8RF
        • Charing Cross Hospital
      • London, 영국, EC1A 7BE
        • St Bartholomew's Hospital
      • Manchester, 영국, M20 4BX
        • The Christie NHS Foundation Trust Christie Hospital
      • Plymouth, 영국, PL6 8QH
        • Derriford Hospital-Department of Medical Oncology
      • Sheffield, 영국, S10 2 RX
        • University of Sheffield
      • Southampton, 영국, SO16 6YD
        • Southampton General Hospital
      • Sutton, 영국, SM2 5NG
        • Royal Marsden Hospital
      • Graz, 오스트리아, 8036
        • LKH-Univ. Klinikum Graz
      • Linz, 오스트리아, 4020
        • Ordensklinikum Linz GmbH Elisabethinen
      • Salzburg, 오스트리아, 5020
        • LKH - Universitätsklinikum der PMU Salzburg
      • Vienna, 오스트리아, 1020
        • Krankenhaus der Barmherzigen Brüder
      • Vienna, 오스트리아, A-1090
        • Medical University Vienna MUV
      • Dnipro, 우크라이나, 49102
        • Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
      • Dnipro, 우크라이나, 49100
        • Municipal Institution 'Clinical Oncology Dispensary' Under Dnipropetrovsk Regional Council
      • Dnipropetrovsk, 우크라이나, 49005
        • MI Dnipropetrovsk Region Clinical Hospital n a I.I.Mechnikov
      • Ivano-Frankivsk, 우크라이나, 76008
        • Ivano-Frankivsk Regional Clinical Hospital
      • Kharkiv, 우크라이나, 61070
        • Municipal non-profit enterprise 'Regional Center of Oncology'
      • Kharkiv, 우크라이나, 61037
        • Regional Medical Clinical Center for Urology and Nephrology named after V.I. Shapoval
      • Kyiv, 우크라이나, 03022
        • National Cancer Institute
      • Kyiv, 우크라이나, 03115
        • State Institution Institute of Urology NAMS of Ukraine based on Kyiv City Clinical Oncology Center
      • Lviv, 우크라이나, 79010
        • Communal Noncommercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital'
      • Uzhhorod, 우크라이나, 88000
        • Transkarpathian Regional University Oncology Clinic
      • Vinnitsa, 우크라이나, 21029
        • Podilskiy Regional Center of Oncology
      • Zaporizhzhya, 우크라이나, 69040
        • Zaokod
      • Zaporizhzhya, 우크라이나, 69600
        • Zaporizhzhia medical Academy of postgraduate education, Zaporizhzhia Regoinal Clinical Hospital
      • Haifa, 이스라엘, 31096
        • Rambam Health Care Campus
      • Jerusalem, 이스라엘, 91120
        • Hadassah Medical Center
      • Kfar Saba, 이스라엘, 44281
        • Meir Medical Center
      • Petach Tikvah, 이스라엘, 49100
        • Rabin Medical Center, Beilinson Hospital
      • Tel Aviv, 이스라엘, 64239
        • Sourasky Medical Center
      • Tel HaShomer, 이스라엘, 52621
        • The Chaim Sheba Medical Center
      • Tzrifin, 이스라엘, 70300
        • Assaf Harofeh Medical Center
      • Alessandria, 이탈리아, 15121
        • Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo Alessandria
      • Arezzo, 이탈리아, 52100
        • Ospedale S. Donato - Asl 8 Arezzo
      • Aviano, 이탈리아, 33081
        • CRO IRCCS Istituto Nazionale Tumori
      • Bergamo, 이탈리아, 24127
        • Azienda Ospedaliera Papa Giovanni XXIII
      • Brescia, 이탈리아, 25123
        • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
      • Cremona, 이탈리아, 26100
        • Istituti Ospitalieri di Cremona, AO di Cremona
      • Florence, 이탈리아, 50139
        • Oncologia Medica
      • Genova, 이탈리아
        • SPDC Villa Scassi
      • Meldola, 이탈리아, 47014
        • IRST Meldola Forli
      • Milan, 이탈리아, 20132
        • IRCCS Ospedale San Raffaele
      • Milan, 이탈리아, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Milan, 이탈리아, 20141
        • European Institute of Oncology
      • Modena, 이탈리아, 41124
        • AOU Policlinico di Modena
      • Naples, 이탈리아, 80131
        • IRCCS-Fondazione Pascale
      • Novara, 이탈리아, 28100
        • Ospedale Maggiore della Carita
      • Orbassano, 이탈리아, 10043
        • Aou San Luigi Gonzaga
      • Padova, 이탈리아, 35128
        • Istituto Oncologico Veneto Iov Irccs Padova
      • Parma, 이탈리아, 43126
        • AOU di Parma
      • Pavia, 이탈리아, 27100
        • IRCCS Policlinico San Matteo
      • Pavia, 이탈리아, 27100
        • Ist. Clinici Scientifici Maugeri - Unità Operativa di Oncolo
      • Pisa, 이탈리아, 56126
        • Azienda Ospedaliero Universitaria Pisana
      • Poggibonsi (SI), 이탈리아, 53100
        • Usl 7 Siena - Ospedale Alta Valdelsa ASL TOSCANA SUD-EST
      • Province of Macerata, 이탈리아, 62100
        • UOC Oncologia Ospedale Provinciale di Macerata
      • Roma, 이탈리아, 00168
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Siena, 이탈리아, 53100
        • Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte
      • Torino, 이탈리아, 10123
        • Oncologia Medica-Città Della Salute E Della Scienza Di Torino
      • Torrette Di Ancona, 이탈리아, 60126
        • Azienda Ospedaliero - Universitaria Ospedali Riuniti
      • Chiba, 일본, 260-8717
        • Chiba Cancer Center
      • Hirosaki, 일본, 036-8563
        • Hirosaki University Hospital
      • Kashiwa, 일본, 277 8577
        • National Cancer Center Hospital East
      • Kita Gun, 일본, 761 0793
        • Kagawa University Hospital
      • Kobe, 일본, 650-0047
        • Kobe City Medical Center General Hospital
      • Koshigaya, 일본, 343-8555
        • Dokkyo Medical University Saitama Medical Center
      • Matsuyama, 일본, 791-0280
        • Aso Co.,Ltd Iizuka Hospital
      • Miyazaki, 일본, 889-1692
        • University of Miyazaki Hospital
      • Nagano, 일본, 381-8551
        • Nagano Municipal Hospital
      • Nagoya, 일본, 464 8681
        • Aichi Cancer Center Hospital
      • Osaka, 일본, 545 8586
        • Osaka City University Hospital
      • Osaka, 일본, 541 8567
        • Osaka International Cancer Institute
      • Sagamihara, 일본, 252-0375
        • Kitasato University Hospital
      • Sakura, 일본, 285-8741
        • Toho University Sakura Medical Center
      • Sapporo, 일본, 003-0804
        • National Hospital Organization Hokkaido Cancer Center
      • Shinjuku-ku, 일본, 162-8666
        • Tokyo Women's Medical University Hospital
      • Tokyo, 일본, 105-8470
        • Toranomon Hospital
      • Tokyo, 일본, 135 8550
        • The Cancer Institute Hospital of JFCR 1
      • Tsukuba, 일본, 305 8576
        • University of Tsukuba Hospital
      • Ube, 일본, 755-8505
        • Yamaguchi University Hospital
      • Yokohama, 일본, 232 0024
        • Yokohama City University Medical Center
      • Ōsaka-sayama, 일본, 589-8511
        • Kindai University Hospital
      • Ōta-ku, 일본, 373-8550
        • Gunma Prefectural Cancer Center
      • Beijing, 중국, 100730
        • Beijing Hospital
      • Beijing, 중국, 100730
        • Peking Union Medical College Hospital
      • Beijing, 중국, 100191
        • Peking University Third Hospital
      • Beijing, 중국, 100050
        • Beijing Friendship Hospital
      • Beijing, 중국, 100034
        • Peking University First Hospital
      • Beijing, 중국, 100021
        • Cancer Hospital Chinese Academy of Medical Sciences
      • Changchun, 중국, 130021
        • The First Bethune Hospital of Jilin University
      • Chengdu, 중국, 610041
        • Sichuan University Huaxi Hospital
      • Chengdu, 중국, 610000
        • Sichuan Provincial Peoples Hospital
      • Chongqing, 중국, 400030
        • Chongqing University Cancer Hospital
      • Guangzhou, 중국, 510180
        • Guangzhou First Municipal People's Hospital
      • Guangzhou, 중국, 510120
        • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
      • Guangzhou, 중국, 510060
        • Sun Yat Sen University Cancer Center
      • Hangzhou, 중국, 310014
        • Zhejiang Provincial People's Hospital
      • Hangzhou, 중국, 310020
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Nanchang, 중국, 330006
        • The First Affliated Hospital Of Nanchang University
      • Nanjing, 중국, 210009
        • Jiangsu Cancer Hospital
      • Nanjing, 중국, 210008
        • Nanjing Drum Tower Hospital
      • Shanghai, 중국, 200127
        • Renji Hospital, Shanghai Jiaotong University School of Medicine
      • Shanghai, 중국, 200400
        • Huadong Hospital Affiliated to Fudan University
      • Shenyang, 중국, 110004
        • Shengjing Hospital Of China Medical University
      • Shenzhen, 중국, 518055
        • Shenzhen university General Hospital
      • Wenzhou, 중국, 325000
        • First Affiliated Hospital Of Wenzhou Medical College
      • Xi'an, 중국, 710061
        • The First Affiliated Hospital of Xian Jiaotong University
    • British Columbia
      • Kelowna, British Columbia, 캐나다, V1Y 5L3
        • BC Cancer Agency - Southern Interior
      • Vancouver, British Columbia, 캐나다, V5Z 4E6
        • Vancouver Cancer Centre
    • Manitoba
      • Winnipeg, Manitoba, 캐나다, R3E 0V9
        • Cancercare Manitoba
    • Ontario
      • Thunder Bay, Ontario, 캐나다, P7B 6V4
        • Thunder Bay Regional Health Sciences Centre
      • Toronto, Ontario, 캐나다, M5G 2M9
        • Princess Margaret Hospital- UHN
    • Saskatchewan
      • Regina, Saskatchewan, 캐나다, S4T 7T1
        • Saskatchewan Cancer Agency (SCA) - Allan Blair Cancer Centre
      • Adana, 터키 (Türkiye), 01120
        • Baskent University Adana Practice and Research Center Kisla Health Campus
      • Ankara, 터키 (Türkiye), 6100
        • Hacettepe University Medical Faculty
      • Istanbul, 터키 (Türkiye), 34098
        • Istanbul Universitesi Cerrahpasa Tip Fakultesi
      • Istanbul, 터키 (Türkiye), 34147
        • Bakirkoy Training and Research Hospital
      • Istanbul, 터키 (Türkiye), 34722
        • T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
      • Istanbul, 터키 (Türkiye), 34214
        • Medipol Mega University Hospital
      • Istanbul, 터키 (Türkiye), 34093
        • Bezmialem University Medical Faculty
      • Istanbul, 터키 (Türkiye), 34890
        • Pendik Training and Research Hospital
      • Izmir, 터키 (Türkiye), 35340
        • Dokuz Eylul Universitesi Tip Fakultesi
      • Izmir, 터키 (Türkiye), 35100
        • Ege University
      • Kocaeli, 터키 (Türkiye)
        • Kocaeli University Medical Faculty
      • Malatya, 터키 (Türkiye), 44400
        • Inonu Universitesi Turgut Ozal Tip Merkezi, Ic Hastaliklari
      • Lisbon, 포르투갈, 1400-038
        • Champalimaud Foundation Champalimaud Centre
      • Lisbon, 포르투갈, G1R 2J6
        • Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
      • Lisbon, 포르투갈, 1500-458
        • Hospital Lusíadas
      • Lisbon, 포르투갈, 1649-035
        • H. Santa Maria - Centro Hospitalar de Lisboa Norte
      • Porto, 포르투갈, 4200072
        • Instituto Portugues de Oncologia
      • Bydgoszcz, 폴란드, 85 796
        • Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy
      • Warsaw, 폴란드, 02-507
        • Centralny Szpital Kliniczny MSWiA w Warszawie
      • Warsaw, 폴란드, 02-781
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
      • Wroclaw, 폴란드, 50 556
        • Uniwersytecki Szpital Kliniczny we Wroclawiu
      • Angers, 프랑스, 49055
        • Institut de Cancerologie de l Ouest ICO
      • Besançon, 프랑스, 25030
        • Hopital Jean Minjoz
      • Bordeaux, 프랑스, 33000
        • Institut Bergonie
      • Brest, 프랑스, 29609
        • CHRU Brest - Hopital Morvan
      • Clermont-Ferrand, 프랑스, 63011
        • Centre Jean Perrin
      • Dijon, 프랑스, 21079
        • Centre Georges-François Leclerc
      • Lille, 프랑스, 59000
        • Centre Oscar Lambret
      • Lille, 프랑스, 59000
        • Hôpital Privé Le Bois
      • Lorient, 프랑스, 56322
        • Groupe Hospitalier Bretagne Sud
      • Marseille, 프랑스, 13005
        • Hopital de la Timone
      • Montpellier, 프랑스, 34298
        • Institut Regional du Cancer de Montpellier Val d'Aurelle
      • Nice, 프랑스, 06189
        • Centre Antoine Lacassagne
      • Nîmes, 프랑스, 30029
        • Institut de Cancérologie du Gard
      • Paris, 프랑스, 75475
        • Hospital Saint-Louis
      • Paris, 프랑스, 75015
        • Hopital Europeen Georges-Pompidou
      • Pierre-Bénite, 프랑스, 69495
        • Hospices Civils de Lyon HCL
      • Poitiers, 프랑스, 86021
        • CHU De Poitiers
      • Rennes, 프랑스, 35062
        • Centre Eugene Marquis
      • Ris-Orangis, 프랑스, 91130
        • Centre de radiothérapie et d'Oncologie médicale de l'Essonne
      • Saint-Priest-en-Jarez, 프랑스, 42271
        • Institut de Cancérologie de Loire
      • Strasbourg, 프랑스, 67098
        • Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
      • Toulouse, 프랑스, 31059
        • Institut Claudius Regaud
      • Valenciennes, 프랑스, 59300
        • Centre Les Dentellieres
      • Villejuif, 프랑스, 94805
        • Institut Gustave Roussy
      • Budapest, 헝가리, 1082
        • Semmelweis Egyetem
      • Budapest, 헝가리, 1122
        • Országos Onkológiai Intézet, Urogenitális Tumorok és Klinikai Farmakológiai Osztály
      • Budapest, 헝가리, H-1145
        • Budapesti Uzsoki Utcai Korhaz
      • Nyíregyháza, 헝가리, 04400
        • Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz
      • Pécs, 헝가리, 7624
        • Pecsi Tudomanyegyetem Klinikai Kozpont
      • Camperdown, 호주, 2050
        • Chris O'Brien Lifehouse
      • Frankston, 호주, 3199
        • Peninsula & South Eastern Haematology and Oncology Group
      • Kogarah, 호주, 2217
        • St George Hospital
      • Melbourne, 호주, 3000
        • Peter MacCallum Cancer Centre
      • Melbourne, 호주, 3199
        • Frankston Hospital
      • Murdoch, 호주, 6150
        • Fiona Stanley Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Histologic demonstration of transitional cell carcinoma of the urothelium. Minor components ( less than [<] 50 percent [%] overall) of variant histology such as glandular or squamous differentiation, or evolution to more aggressive phenotypes such as sarcomatoid or micropapillary change are acceptable
  • Metastatic or surgically unresectable urothelial cancer
  • Documented progression of disease, defined as any progression that requires a change in treatment, prior to randomization
  • Cohort 1: Prior treatment with an anti-PD-(L) 1 agent as monotherapy or as combination therapy; no more than 2 prior lines of systemic treatment. Cohort 2: No prior treatment with an anti-PD-(L) 1 agent; only 1 line of prior systemic treatment. Subjects who received neoadjuvant or adjuvant chemotherapy and showed disease progression within 12 months of the last dose are considered to have received systemic therapy in the metastatic setting.
  • A woman of childbearing potential who is sexually active must have a negative pregnancy test (beta human chorionic gonadotropin [beta hCG]) at Screening (urine or serum)
  • Participants must meet appropriate molecular eligibility criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
  • Adequate bone marrow, liver, and renal function

Exclusion Criteria:

  • Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 30 days prior to randomization
  • Active malignancies (that is, requiring treatment change in the last 24 months). The only allowed exceptions are: urothelial cancer, skin cancer treated within the last 24 months that is considered completely cured, localized prostate cancer with a gleason score of 6 (treated within the last 24 months or untreated and under surveillance) and localized prostate cancer with a gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence.
  • Symptomatic central nervous system metastases
  • Received prior fibroblast growth factor receptor (FGFR) inhibitor treatment
  • Known allergies, hypersensitivity, or intolerance to erdafitinib or its excipients
  • Current central serous retinopathy (CSR) or retinal pigment epithelial detachment of any grade.
  • History of uncontrolled cardiovascular disease
  • Impaired wound healing capacity defined as skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort 1 (Arm 1A): Erdafitinib

Participants will be screened based on Fibroblast Growth Factor Receptor Inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events [AEs]). Participants who enter in Long-term extension (LTE) phase will continue to receive the erdafitinib tablet as per investigator's decision.

Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.

다른 이름들:
  • JNJ-42756493

FGFRi CTA will be used to determine molecular eligibility.

실험적: Cohort 1 (Arm 1B): Vinflunine or Docetaxel

Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-[L] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive Vinflunine or Docetaxel until the participant can commercially receive chemotherapy within the local healthcare system.

FGFRi CTA will be used to determine molecular eligibility.

Participants will receive vinflunine 320 mg/m^2 as a 20-minute intravenous infusion.

Participants will receive docetaxel 75 mg/m^2 as a 1 hour intravenous infusion.

실험적: Cohort 2 (Arm 2A): Erdafitinib

Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs). Participants who enter in LTE phase will continue to receive the erdafitinib tablet as per investigator's decision.

Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.

다른 이름들:
  • JNJ-42756493

FGFRi CTA will be used to determine molecular eligibility.

실험적: Cohort 2 (Arm 2B): Pembrolizumab

Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive the pembrolizumab until 2 years after the first dose of pembrolizumab (at start of study) or until the participant can commercially receive pembrolizumab within the local healthcare system, whichever comes first.

FGFRi CTA will be used to determine molecular eligibility.

Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall Survival (OS)
기간: From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months)

Overall survival was measured from the date of randomization to the date of the participant's death.

From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months)

2차 결과 측정

결과 측정
측정값 설명
기간
Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
기간: From randomization (3 days prior to Cycle 1 Day 1) until disease progression or relapse from CR or death (maximum up to 51.7 months)

PFS was defined as the time from the date of randomization to the date of disease progression or relapse from complete response (CR) based on investigator assessment using RECIST v 1.1, or death due to any cause, whichever occurred first. As per RECIST v 1.1, CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to less than (<) 10 millimeters (mm). Progressive disease (PD) was defined as at least 20 percent (%) increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of greater than or equal to (>=) 5 mm or appearance of at least 1 new lesion.

From randomization (3 days prior to Cycle 1 Day 1) until disease progression or relapse from CR or death (maximum up to 51.7 months)
Objective Response Rate (ORR) Per RECIST Version 1.1
기간: From start of the treatment (Day 1 Cycle 1) up to maximum of 51.7 months

ORR was defined as the percentage of participants who achieved CR or partial response (PR) as determined by investigator per RECIST v1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

From start of the treatment (Day 1 Cycle 1) up to maximum of 51.7 months
Change From Baseline in Physical Functioning Scales of the Functional Assessment of Cancer Therapy - Bladder Cancer (FACT-Bl)
기간: Baseline up to Cycle 11 (each cycle was of 21 days)

The FACT-Bl consisted of 39 items, with 5-point Likert scales, covering 5 primary domains: physical well-being, social/family well-being, emotional well-being, functional well-being and additional concerns for participants with bladder cancer. The response options ranged from 0 to 4 where, 0='Not at all" and 4= "very much." FACT-Bl total score ranged from 0 (worst) to 156 (best). The higher the score, the better the quality of life (QOL). The baseline value was defined as the value collected at the time closest to but prior to the randomization.

Baseline up to Cycle 11 (each cycle was of 21 days)
Time Until Symptom Deterioration
기간: Randomization (3 days prior to Cycle 1 Day 1) up to maximum of 51.7 months

Time until symptom deterioration was defined as the first time to increase in urinary bladder cancer symptoms score from the day of randomization beyond a meaningful change threshold compared to baseline. The urinary bladder cancer symptom score was subset of FACT-Bl which included 3 items related to urinary symptoms, 5-point Likert scale. Response options ranged from 0 to 4, 0 = Not at all, 1= A little bit, 2= Somewhat, 3=Quite a bit, 4 = Very much. A response of 0 indicated no symptoms and 4 indicated severe symptoms. Total sum scores ranged from 0 to 12, higher scores indicate relatively poor quality of life.

Randomization (3 days prior to Cycle 1 Day 1) up to maximum of 51.7 months
Percentage of Participants With Shift From Baseline in Patient-Global Impression of Severity (PGIS)
기간: Baseline, 51.7 months

The PGI-S was a single item patient-reported measure assessing participants' impression of severity in bladder cancer symptoms. It uses a 4-point Likert scale as follows: symptoms are: 0-"absent (no symptoms)", 1-"mild", 2-"moderate", 3="severe" and 4= "very severe". Percentage of participants with shift from baseline in PGIS score were reported. A negative shift from baseline in PGIS score indicated Improvement and positive shift from baseline in PGIS score indicated Worsening. The baseline value was defined as the value collected at the time closest to but prior to the randomization.

Baseline, 51.7 months
Change From Baseline in Utility Scale of the European Quality of Life-5 Dimensions-5 Levels Questionnaire (EQ-5D-5L)
기간: Baseline up to Cycle 11 (each cycle was of 21 days)

The EQ-5D-5L was a generic measure of health status. The EQ-5D-5L was a 5-item questionnaire that assessed 5 domains included mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Health utility values generated from the EQ-5D generally range from 0 (a state as bad as being dead) to 1 (full health), with higher scores indicating better QoL. The EQ visual analog scale (VAS) recorded the patient's self-rated health on a VAS, ranged from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better QoL. The baseline value was defined as the value collected at the time closest to but prior to the randomization.

Baseline up to Cycle 11 (each cycle was of 21 days)
Change From Baseline in Visual Analog Scale (VAS) of the European Quality of Life-5 Dimensions-5 Levels Questionnaire (EQ-5D-5L)
기간: Baseline up to Cycle 11 (each cycle was of 21 days)

The EQ-5D-5L was a generic measure of health status. The EQ-5D-5L was a 5-item questionnaire that assessed 5 domains included mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Health utility values generated from the EQ-5D generally range from 0 (a state as bad as being dead) to 1 (full health), with higher scores indicating better QoL. The EQ VAS recorded the patient's self-rated health on a VAS, ranged from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better QoL. The baseline value was defined as the value collected at the time closest to but prior to the randomization.

Baseline up to Cycle 11 (each cycle was of 21 days)
Duration of Response (DOR) as Per RECIST Version 1.1
기간: From date of first documented response to date of first documented PD or death whichever occurred first (maximum up to 51.7 months)

DOR was defined as time from the date of initial documentation of an overall response (CR or PR) to the date of first documented evidence of progressive disease (PD) (or relapse for participants who experience CR) or death. As per RECIST Version 1.1: CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of >=5 mm or appearance of at least 1 new lesion.

From date of first documented response to date of first documented PD or death whichever occurred first (maximum up to 51.7 months)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
기간: From start of the treatment (Day 1 Cycle 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (maximum up to 51.7 months)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were the events between first dose of study drug and up to 30 days after last dose or before start of new anticancer therapy, whichever occurred first. All TEAEs including serious and non-serious events were reported in this outcome measure.

From start of the treatment (Day 1 Cycle 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (maximum up to 51.7 months)
Number of Participants With Shift From Baseline Grade Less Than or Equal to (<=) 2 to Grade Greater Than or Equal to (>=) 3 Post-Baseline in Laboratory Parameter: Hematology
기간: From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)

Hematology parameters included: hemoglobin, platelet count, white blood cell (WBC) count, and absolute neutrophil count (ANC). According to national cancer institute (NCI)-common terminology criteria for adverse events (CTCAE) version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE and Grade 0= normal. In this outcome measure number of participants with shifts from baseline (BL) Grade <= 2 to Grade >=3 post-baseline in any of hematology parameters are reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only those categories in which at least one participant had data were reported in this outcome measure.

From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
Number of Participants With Shift From Baseline Grade <= 2 to Grade >=3 Post-Baseline in Laboratory Parameter: Chemistry
기간: From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)

Chemistry parameters included: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, chloride, creatinine, bicarbonate, corrected calcium, magnesium, potassium, sodium, serum phosphate, serum parathyroid hormone. According to NCI-CTCAE version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE and Grade 0= normal. In this outcome measure number of participants with shifts from baseline (BL) Grade <= 2 to Grade >=3 post-baseline in any of chemistry parameters are reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only those categories in which at least one participant had data were reported in this outcome measure.

From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
Number of Participants With Abnormalities in Electrocardiograms (ECG) Parameters
기간: Day 1 of Cycle 2 and 4 (Each Cycle 21 days)

Number of participants with abnormalities in ECG parameters were reported. The ECG variables included heart rate, RR interval, PR interval, QRS interval, QT interval and QT corrected according to Fridericia's formula (QTcF). ECG abnormality criteria include: Heart rate: Low <50 beats per minute (bpm); High > 100 bpm, RR interval: Low < 600 milliseconds (ms); High > 1000 ms, QT interval: High > 500 ms, QTc interval: High > (450 ms for males, 470 ms for females); increase to >500 ms.

Day 1 of Cycle 2 and 4 (Each Cycle 21 days)
Change From Baseline in Vital Signs: Weight
기간: Baseline, 51.7 months

Changes from baseline in vital signs (weight) was reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug.

Baseline, 51.7 months
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Amsler Grid Test
기간: From baseline up to maximum of 51.7 months

Number of participants with shift from baseline to worst post-baseline in Amsler grid test was reported. Baseline and post-baseline visit findings included normal, abnormal CS (clinically significant) and abnormal NCS (not clinically significant). Clinical significance was determined by investigator's assessment. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported.

From baseline up to maximum of 51.7 months
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Visual Acuity
기간: From baseline up to maximum of 51.7 months

Number of participants with shift from baseline to worst post-baseline in visual acuity (VA) was reported. Worst post-baseline was defined as the visual acuity value that resulted in the largest change from baseline value for either eye. Baseline value was considered for the eye that reported the worst-post baseline value. Baseline and post-baseline visit visual acuity findings included: <= 20/30, >20/30 to <= 20/40, >20/40 to <= 20/80, >20/80 to <= 20/120, >20/120 to <= 20/160, >20/160 to <= 20/200, >20/200. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening in visual acuity from baseline value to worst post-baseline measurement was reported.

From baseline up to maximum of 51.7 months
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Optical Coherence Tomography: Subretinal Fluid
기간: From baseline up to maximum of 51.7 months

Number of participants with shift from baseline to worst post-baseline in optical coherence tomography for subretinal fluid was reported. At the baseline visit, findings may have been absent or present/visible. At all post-baseline visits, findings were compared to baseline and results may have been increased, decreased, stable or resolved. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only category (shift from absent at baseline to increased at post-baseline) in which at least one participant had data for worsening post-baseline measurement was reported.

From baseline up to maximum of 51.7 months
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Optical Coherence Tomography: Retinal Pigment Epithelium (RPE) Elevation
기간: From baseline up to maximum of 51.7 months

Number of participants with shift from baseline to worst post-baseline in optical coherence tomography for RPE elevation was reported. At the baseline visit, findings may have been absent or present/visible. At all post-baseline visits, findings were compared to baseline and results may have been increased, decreased, stable or resolved. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported.

From baseline up to maximum of 51.7 months
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Slit Lamp Biomicroscopy: Retinal Assessment
기간: From baseline up to maximum of 51.7 months

Number of participants with shift from baseline to worst post-baseline in slit lamp biomicroscopy examination for retinal assessment was reported. Baseline and post-baseline visit findings included normal, abnormal CS and abnormal NCS. Clinical significance was determined by investigator's assessment. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported.

From baseline up to maximum of 51.7 months
Oral Clearance (CL/F) of Erdafitinib
기간: Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle was of 21 days)

Clearance was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes.

Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle was of 21 days)
Area Under the Plasma Concentration-Time Curve From Time Zero to Time 't' (AUC[0-t]) of Erdafitinib
기간: Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle is of 21 days)

Area under the plasma concentration time-curve from time zero to the time t (AUC[0-t]) was reported.

Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle is of 21 days)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2018년 3월 23일

기본 완료 (실제)

2024년 4월 15일

연구 완료 (추정된)

2027년 12월 31일

연구 등록 날짜

최초 제출

2017년 12월 20일

QC 기준을 충족하는 최초 제출

2018년 1월 3일

처음 게시됨 (실제)

2018년 1월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CR108401
  • 2017-002932-18 (EudraCT 번호)
  • 42756493BLC3001 (기타 식별자: Janssen Research & Development, LLC)
  • 2017 (미국 NIH 보조금/계약)
  • 2023-510296-56-00 (레지스트리 식별자: EUCT number)
  • 2023 (미국 NIH 보조금/계약)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다